{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:52Z","timestamp":1786119232559,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    Undifferentiated primary liver carcinoma (UPLC) is an exceedingly rare hepatic malignancy lacking hepatocytic or cholangiocytic differentiation, and its clinicopathologic and molecular characteristics remain poorly defined. We retrospectively analyzed 25 UPLC cases from a single Chinese institution over an 8-year period and performed whole-exome sequencing (WES) to delineate the genomic landscape, combined with multiplex immunofluorescence (mIF), routine histopathology, and immunohistochemistry (IHC) for phenotypic assessment. UPLC exhibits marked histologic and immunophenotypic heterogeneity, with all cases negative for classic hepatobiliary differentiation markers; albumin RNA in situ hybridization (Alb-ISH) demonstrates limited diagnostic utility due to low positivity. Compared with conventional hepatocellular carcinoma (HCC) from the Cancer Genome Atlas (TCGA), UPLC demonstrates a distinct mutational profile, with frequent alterations in 5 key oncogenic pathways (Hippo, NOTCH, WNT, RTK-RAS, and TP53) in 96.0% of cases and a higher mutation frequency of core pathway genes than HCC.\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    promoter hotspot mutations were identified in a subset but showed no association with clinicopathologic features or survival.\n                    <jats:italic toggle=\"yes\">AHNAK2<\/jats:italic>\n                    was the most frequently mutated gene (68.0%) and is rarely altered in HCC or intrahepatic cholangiocarcinoma (ICC). Patients with\n                    <jats:italic toggle=\"yes\">AHNAK2<\/jats:italic>\n                    -mutated UPLC had significantly shorter overall survival, elevated tumor mutational burden (TMB), and markedly reduced infiltration of CD4\u207a, CD8\u207a, CD20\u207a, and CD68\u207a immune cells. These findings support the recognition of UPLC as a clinically aggressive and molecularly distinct entity and indicate that the\n                    <jats:italic toggle=\"yes\">AHNAK2<\/jats:italic>\n                    mutation may serve as a potential prognostic biomarker in this rare malignancy.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002554","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:00:19Z","timestamp":1777050019000},"page":"849-863","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Whole-Exome Sequencing Identifies Frequent AHNAK2 Mutations With Prognostic Significance in Undifferentiated Primary Liver Carcinoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Ziqi","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Pathology and Institute of Clinical Pathology"},{"name":"NHC Key Laboratory of Transplant Engineering and Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Pathology and Institute of Clinical Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyin","family":"Chen","sequence":"additional","affiliation":[{"name":"The College of Computer Science and the Institute for Industrial Internet Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwen","family":"Zhu","sequence":"additional","affiliation":[{"name":"West China School of Clinical Medicine, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanjing","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy, Cancer Center, West China Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenru","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Institute of Clinical Pathology"},{"name":"NHC Key Laboratory of Transplant Engineering and Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Institute of Clinical Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Institute of Clinical Pathology"},{"name":"NHC Key Laboratory of Transplant Engineering and Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"R1-20260617","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","article-title":"Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma","volume":"32","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"R2-20260617","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/diagnostics13091542","article-title":"The role of immunohistochemistry in the differential diagnosis between intrahepatic cholangiocarcinoma, hepatocellular carcinoma and liver metastasis, as well as its prognostic value","volume":"13","author":"Mocan","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R3-20260617","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R4-20260617","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-20260617","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R6-20260617","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R7-20260617","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2169\/internalmedicine.4177-24","article-title":"A rare case of undifferentiated carcinoma of the liver arising in the context of primary biliary cholangitis","volume":"64","author":"Suzuki","year":"2025","journal-title":"Intern Med"},{"key":"R8-20260617","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijscr.2018.07.047","article-title":"A long-term survivor of undifferentiated carcinoma of the liver successfully treated with surgical treatments: a case report and literature review","volume":"51","author":"Hiraki","year":"2018","journal-title":"Int J Surg Case Rep"},{"key":"R9-20260617","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s13691-020-00436-0","article-title":"Primary undifferentiated carcinoma with osteoclast-like giant cells in liver and rapidly developing multiple metastases after curative hepatectomy: a case report","volume":"9","author":"Kamitani","year":"2020","journal-title":"Int Cancer Conf J"},{"key":"R11-20260617","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/PAS.0000000000000343","article-title":"Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms","volume":"39","author":"Shahid","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R12-20260617","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/PAS.0000000000000585","article-title":"BSEP and MDR3: useful immunohistochemical markers to discriminate hepatocellular carcinomas from intrahepatic cholangiocarcinomas and hepatoid carcinomas","volume":"40","author":"Fujikura","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R13-20260617","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/PAS.0000000000002393","article-title":"CPZ: A highly sensitive diagnostic biomarker for the differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma, particularly in poorly differentiated hepatocellular carcinoma","volume":"49","author":"Deng","year":"2025","journal-title":"Am J Surg Pathol"},{"key":"R14-20260617","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/ajcp\/aqy030","article-title":"Detection of albumin expression by RNA in situ hybridization is a sensitive and specific method for identification of hepatocellular carcinomas and intrahepatic cholangiocarcinomas","volume":"150","author":"Lin","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"R15-20260617","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41379-021-00970-z","article-title":"Molecular features of primary hepatic undifferentiated carcinoma","volume":"35","author":"Tsai","year":"2022","journal-title":"Mod Pathol"},{"key":"R16-20260617","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/PAS.0000000000002116","article-title":"Genomic analysis in the categorization of poorly differentiated primary liver carcinomas","volume":"47","author":"Kikuchi","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"R17-20260617","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat Commun"},{"key":"R18-20260617","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1073\/pnas.0308619101","article-title":"The AHNAKs are a class of giant propeller-like proteins that associate with calcium channel proteins of cardiomyocytes and other cells","volume":"101","author":"Komuro","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-20260617","doi-asserted-by":"crossref","first-page":"14121","DOI":"10.1074\/jbc.M114.554816","article-title":"Periaxin and AHNAK nucleoprotein 2 form intertwined homodimers through domain swapping","volume":"289","author":"Han","year":"2014","journal-title":"J Biol Chem"},{"key":"R20-20260617","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1073\/pnas.89.12.5472","article-title":"A human gene (AHNAK) encoding an unusually large protein with a 1.2-microns polyionic rod structure","volume":"89","author":"Shtivelman","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"R21-20260617","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fgene.2018.00108","article-title":"Identification and validation of a diagnostic and prognostic multi-gene biomarker panel for pancreatic ductal adenocarcinoma","volume":"9","author":"Klett","year":"2018","journal-title":"Front Genet"},{"key":"R22-20260617","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.7150\/thno.18198","article-title":"AHNAK2 is a novel prognostic marker and oncogenic protein for clear cell renal cell carcinoma","volume":"7","author":"Wang","year":"2017","journal-title":"Theranostics"},{"key":"R23-20260617","doi-asserted-by":"crossref","first-page":"12893","DOI":"10.2147\/OTT.S281517","article-title":"AHNAK2 promotes migration, invasion, and epithelial-mesenchymal transition in lung adenocarcinoma cells via the TGF-\u03b2\/Smad3 pathway","volume":"13","author":"Liu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"R24-20260617","doi-asserted-by":"crossref","first-page":"107185","DOI":"10.1016\/j.intimp.2020.107185","article-title":"AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: evidence from integrated analysis","volume":"90","author":"Zheng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R25-20260617","doi-asserted-by":"crossref","first-page":"798401","DOI":"10.3389\/fonc.2022.798401","article-title":"Deleterious AHNAK2 mutation as a novel biomarker for immune checkpoint inhibitors in non-small cell lung cancer","volume":"12","author":"Cui","year":"2022","journal-title":"Front Oncol"},{"key":"R26-20260617","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:47:58Z","timestamp":1786038478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002554","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]}}}